SCHEMBL675341

SCHEMBL675341

CCN(CC)C(=O)c1ccc2[nH]c3nccc(Cl)c3c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR9 Q9NR96 3/20 0.50
TLR8 Q9NR97 3/20 0.50
TLR7 Q9NYK1 3/20 0.50
HSP90AA1 P07900 2/20 0.50
HSP90AB1 P08238 2/20 0.50
ERBB2 P04626 3/20 0.48
PTK6 Q13882 2/20 0.48
ALDH1A1 P00352 2/20 0.46
MAPT P10636 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
UTS2R Q9UKP6 2/20 0.46
ALK Q9UM73 1/20 0.45
GNRHR P30968 3/20 0.43
TSHR P16473 1/20 0.43
AURKA O14965 1/20 0.43
AURKB Q96GD4 1/20 0.43
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
GRM5 P41594 1/20 0.42
ITK Q08881 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL675507 0.84 ERBB2 (0.47) TLR9TLR8TLR7ERBB2PTK6
SCHEMBL674994 0.83 ERBB2 (0.50) ERBB2PTK6ALDH1A1UTS2RALK
SCHEMBL676178 0.81 GRM5 (0.46) TLR9TLR8TLR7HSP90AA1HSP90AB1
SCHEMBL674216 0.80 ERBB2 (0.48) ERBB2PTK6ALDH1A1UTS2RALK
SCHEMBL3668044 0.80 ERBB2 (0.41) TLR9TLR8TLR7ERBB2PTK6
SCHEMBL3668046 0.80 ERBB2 (0.41) TLR9TLR8TLR7ERBB2PTK6
SCHEMBL674944 0.79 HSP90AA1 (0.46) TLR9TLR8TLR7HSP90AA1HSP90AB1
SCHEMBL675910 0.79 PARP1 (0.46) ERBB2PTK6UTS2RALKTSHR
SCHEMBL676137 0.79 AURKA (0.50) ERBB2PTK6ALDH1A1ALKAURKA
Diethylamine SCHEMBL3668048 0.78 ERBB2 (0.45) TLR9TLR8TLR7ERBB2PTK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed
EP-2161271-A1 Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl Università Degli Studi Di Milano - Bicocca (IT) 2010-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 TLR9 3374/4885TLR8 3806/4885TLR7 3780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.